Siemens PETNET Signs Agreement to Manufacture, Distribute Lilly’s PET Imaging Agent
November 9, 2011 – PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA Inc., has entered into a nationwide commercial agreement with Eli Lilly and Company that grants Siemens PETNET Solutions the right to manufacture and distribute Lilly’s molecular imaging agent, which is currently under review by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging.
With the industry’s largest network of PET biomarker production facilities worldwide, Siemens PETNET Solutions is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly’s molecular imaging agent in the United States, should it be FDA approved. Additionally, should Lilly’s molecular imaging agent be approved in markets outside the United States, the companies would consider expanding this commercial agreement to those markets as well.
“This commercial agreement with Lilly is another proof point that Siemens is at the forefront of providing leading diagnostic solutions that advance our mission: to provide physicians and patients with an integrated approach to diagnosing diseases,” said Britta Fuenfstueck, CEO of Molecular Imaging, Siemens Healthcare. “Optimized solutions, from tracer manufacturing to innovative scanner technologies of the Biograph product family of PET/CT and PET/MR products and related processing solutions, support an efficient diagnostic process.”
For more information: www.siemens.com/healthcare
More like this
- PETNET Signs Supply Deal with Lantheus for Cardiac Perfusion Trials
- Siemens, Covidien Agreement Expands Radioisotope Access
- GE Media Day Focuses on Ground-Breaking Research, New Collaborations
- GE, Lilly to Co-Develop In Vitro Diagnostics
- Siemens, UC Davis Partner to Establish PET Radiopharmaceutical Facility